**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings. The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$764,569 Wol.
Mar 31, 2026
June 30
2%
December 31
27%
$764,569 Wol.
June 30
$340,710 Wol.
2%
December 31
$158,977 Wol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings.
The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Wolumen
$764,569Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings.
The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$764,569Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings. The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania